CTOs on the Move

CaptureRx

www.capturerx.com

 
Founded in 2000, San Antonio-based CaptureRx is a healthcare technology company and leading 340B solution provider that puts people first, touching millions of patient lives through customer obsession and innovative products and services that support relationships among payers, providers, pharmacies and patients. Our solutions manage inventory and financial flow for 340B prescriptions filled at contract pharmacies and perform the eligibility checks required to comply with 340B program requirements. Using a process that`s seamless to the covered entity, pharmacy and patient, our Cumulus platform has processed more than 190 million patient encounters and more than 750 million switch claims. Currently, CaptureRx ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.capturerx.com
  • 219 East Houston Street Suite 200
    San Antonio, TX USA 78205
  • Phone: 888.345.6424

Executives

Name Title Contact Details

Similar Companies

ABC Laboratories

Analytical Bio-Chemistry (ABC) Laboratories, Inc. is a GLP and CGMP-compliant contract laboratory with expertise in analytical services and radiolabeling synthesis. From its inception in 1968, ABC Laboratories has been dedicated to solving scientific

Medical Murray

Medical Murray specializes in medical device development, testing and contract manufacturing services - with expertise in catheters, implants, and more.

Pharmascent

Pharmascent is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmacology Research Institute

Pharmacology Research Institute is a Los Alamitos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.